Copied
 
 
Formål
Formål
Selskabets formål er at drive forskning, handel, fabrikation og dermed beslægtet virksomhed primært inden for sundhedssektoren.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 24.06.2014 (3786 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 01.07.1995 (10719 dage).
Ingen historik.
Branche
Branche
Forskning og eksperimentel udvikling indenfor bioteknologi (721100).
Sidst opdateret den 22.12.2007 og angivet som gældende fra 01.01.2008 (6152 dage).
HistorikStartStop
Forskning og eksperimentel udvikling indenfor bioteknologi (721100)01.01.2008
Forskning og udvikling inden for naturvidenskab og teknik (731000)01.07.199531.12.2007
Revision
Revisionfravalgt
false.
Sidst opdateret den 11.03.2015 og angivet som gældende fra 19.06.2002 (8174 dage).
Ingen historik.
Form
Virksomhedsform
60.
Sidst opdateret den 19.06.2002 og angivet som gældende fra 28.05.2002 (8196 dage).
HistorikStartStop
6028.05.2002
8001.07.199527.05.2002
Kontakt
Kontaktoplysninger
info@bioporto.com.
Sidst opdateret den 22.03.2010 og angivet som gældende fra 22.03.2010 (5341 dage).
Ingen historik.
Telefon
Telefonnummer
45290000.
Sidst opdateret den 18.10.2005 og angivet som gældende fra 18.10.2005 (6957 dage).
Ingen historik.
Navne
Binavne
Binavne
ANTIBODYSHOP A/S.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 19.06.2002 (8174 dage).
HistorikStartStop
ANTIBODYSHOP A/S19.06.2002
DIAGNOSTICK A/S19.06.2002
ANTIBODYSHOP ApS01.07.199528.05.2002
DIAGNOSTICK ApS01.07.199528.05.2002
ENTTECH ApS01.07.199528.05.2002
IDEGO ApS01.07.199528.05.2002
Tegningsregel
Tegningsregel
Selskabet tegnes af den samlede bestyrelse, af bestyrelsesformanden sammen med en direktør eller af to direktionsmedlemmer i forening.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 24.06.2014 (3786 dage).
Fortolkning (3 tegningsmuligheder)
bestyrelsen
formanden + 1 direktør
2 direktionsmedlemmer +
Ingen historik.
Ansatte
04.11.2024
Kapital
04.11.2024
Fra årsrapport
Type af revisorbistand:Auditor's report on audited financial statements
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Reporting class B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor’s responsibilities for the audit of the financial statements" section of this auditor’s report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of BioPorto Diagnostics A/S for the financial year 1 January 2023 - 31 December 2023, which comprise the income statement, balance sheet, statement of changes in equity and disclosures, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31 December 2023, and of the results of its operations for the financial year 1 January 2023 - 31 December 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the management review. Our opinion on the financial statements døs not cover the management review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the management review and, in doing so, consider whether the management review is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the management review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management review.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
04.11.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
04.11.2024
Ingen nuværende registrering.
Ingen historik.